News & Events about Compugen Ltd.
Ticker Report
2 months ago
Compugen Ltd. (NASDAQ:CGEN Get Rating) has been given a consensus recommendation of Moderate Buy by the six brokerages that are currently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued...
Compugen's COM701 (anti-PVRIG) in Combination with Nivolumab Demonstrates Preliminary Anti-Tumor Activity and Potent Immune Activation in Metastatic MSS-CRC Patients Compugen's COM701 (anti-PVRIG) in Combination with Nivolumab Demonstrates Preliminary Anti-Tumor Activity and Potent Immune...
Compugen's COM701 (anti-PVRIG) Induces Potent Immune Activation in MSS-CRC Patients Compugen's COM701 (anti-PVRIG) Induces Potent Immune Activation in MSS-CRC Patients PR Newswire HOLON, Israel, Nov. 7, 2022 Anti-tumor activity following blockade of PVRIG with COM701 when added to nivolumab is...
Ticker Report
5 months ago
StockNews.com downgraded shares of Compugen (NASDAQ:CGEN Get Rating) from a hold rating to a sell rating in a report published on Friday. Several other brokerages have also issued reports on CGEN. Jefferies Financial Group lowered Compugen from a buy rating to a hold rating and set a $2.00 ...
Ticker Report
8 months ago
Raymond James Associates raised its holdings in Compugen Ltd. (NASDAQ:CGEN Get Rating) by 5.4% in the 4th quarter, according to its most recent 13F filing with the Securities Exchange Commission. The firm owned 213,510 shares of the biotechnology companys stock after ...